Primary Hodgkin's disease limited to the CNS is exceedingly rare. Little is known regarding etiologic risk factors, optimal management, and prognosis. A case of Hodgkin's disease con ned to the CNS, with cerebrospinal uid negative for cytology, is described in an immunocompetent patient previously treated for hyperthyroidism with 131 I. The patient underwent craniotomy, with resection of two lesions in close proximity within the parenchyma of the temporoparietal lobe. Histopathology revealed classic nodular sclerosing Hodgkin's disease, without evidence of Epstein-Barr viral infection. Treatment included radiation to the whole brain with a boost to the tumor bed. The patient made a full neurologic recovery and remains free of disease recurrence 21 months after treatment. A literature review has identi ed only 9 additional cases. Seven of 8 evaluable patients remain alive and free of recurrence with a median follow-up of 13 months. The risk factors for this presentation remain unde ned. Although followup is short, radiotherapy alone appears to provide excellent disease-free survival. Chemotherapy may be reserved for patients with positive cerebrospinal uid, extracranial disease, or subsequent relapse. Neuro-Oncology 2, 239-243, 2000 (Posted to Neuro-Oncology [serial online], Doc. 00-028, September 6, 2000 H odgkin's disease with CNS involvement is uncommon, even in the HIV-positive population, and usually occurs in the setting of advanced or recurrent disease. Reports of primary Hodgkin's disease conned to the CNS are exceedingly rare. We describe a case of primary CNS Hodgkin's disease in a patient previously treated with 131 I for Grave's hyperthyroidism and review the literature with respect to potential risk factors, management, and treatment outcomes.
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Case Study
A 52-year-old right-handed male truck driver developed sudden onset of headache and confusion. He presented to the emergency department 2 days later with mild disorientation and receptive aphasia. Functional inquiry was negative for fatigue, weight loss, pruritis, fever, and night sweats. Physical examination revealed proptosis, but no evidence of peripheral adenopathy or hepatosplenomegaly. Assessment of cranial nerves, power, sensation, and coordination revealed no abnormalities.
Past health included a history of Grave's hyperthyroidism with ophthalmopathy 4 years earlier. The patient was treated with radioactive iodine at a total dose of 229 mbq (6.2 mCi) administered orally. There was a 40-packyear smoking history . Medication on admission was limited to L-thyroxine, 0.125 mg per day. Family history was negative for cancer.
Initial investigations revealed a normal complete blood cell count, peripheral blood smear, electrolytes, blood urea nitrogen, creatinine, random glucose, and international normalized ratio. Serum lactate dehydrogenase and erythrocyte sedimentation rate were not performed. A CT scan with contrast of the head revealed a contrast-enhancing 1.0 cm left temporoparietal lesion, with signi cant edema and mass effect (Fig. 1) .
Treatment was initiated in the emergency department with phenytoin and dexamethasone. Craniotomy with tumor resection was performed 2 days later. Two mass lesions measuring 8 3 6 3 4 mm and 2 3 2 3 1 mm were removed without complications. The larger lesion was parenchymal, with the smaller adjacent mass adherent to the arachnoid mater.
Pathologic work-up included histologic and immunohistochemical studies, as well as in situ hybridization for Epstein-Barr virus RNA. The surgical specimen was xed in 10% neutral buffered formalin and embedded in paraf n, and sections were stained with hematoxylin and eosin. For immunohistochemical staining, commercially available antibodies and the biotinylated-streptavid in horseradish peroxidase technique were used. In situ hybridization for Epstein-Barr virus RNA was performed using the EBER-1 probe (Novocastra Laboratories, Newcastle upon Tyne, U.K.).
Examination of the hematoxylin-and eosin-stained tissue demonstrated a mixed in ltrate composed of lymphocytes, plasma cells, numerous eosinophils, and large pleomorphic malignant cells separated into vague nodules by fibrous tissue. Numerous multinucleated cells with classic features of Reed-Sternberg cells were present (Fig. 2a) . Lacunar variants and mononuclear variants were frequently identi ed. The Reed-Sternberg cells were CD30- (Fig. 2b) and CD15-positive. They were negative for CD45, CD20, and CD3, although the reactive component revealed a mixed in ltrate of T cells and B cells. Reed-Sternberg cells and lymphocytes were negative for Epstein-Barr virus LMP-1 protein and RNA using the EBER-1 probe.
The patient's postoperative course was uneventful, and the dexamethasone was successfully tapered. He achieved full neurologic recovery and was discharged on phenytoin with no documented seizures.
Subsequent staging work-up included a normal bone marrow aspirate and biopsy. A lumbar puncture yielded clear CSF 2 characterized by normal white cell count, normal protein level, and slightly elevated glucose. The CSF was negative for malignant cells. Ultrasound of liver and CT scan of thorax, abdomen, and pelvis revealed no signi cant abnormality. A whole-body gallium scan was within normal limits. Thyroid ultrasound revealed a small coarse gland with no signi cant abnormality. HIV testing was negative.
The patient was classi ed as Ann Arbor stage IEA. Radiation planning was begun 10 weeks after surgery. The target volume included the whole brain and meninges. The patient was treated supine, immobilized in a plastic shell. A lateral parallel pair was used to deliver a dose of 3000 cGy in 17 fractions to midplane on cobalt-60. The eyes were shielded throughout therapy. A weighted lateral parallel pair was used to boost original sites of gross disease with a margin of 2 cm to a dose of 500 cGy in 3 fractions. Radiation was well tolerated.
Follow-up CT scans at 1, 6, 12, and 20 months posttreatment revealed no evidence of recurrence. At 21 months from completion of radiation treatment, the patient remains well with no evidence of local or systemic Hodgkin's disease.
Discussion
CNS Hodgkin's disease has been described in patients with disseminated disease, particularly those with relapse involving extranodal sites (Cuttner et al., 1979; Dujovny et al., 1980; Sapozink and Kaplan, 1983) . Primary Hodgkin's disease isolated to the CNS is exceedingly rare (Algers et al., 1981; Wood and Coltman, 1973) . A review of the literature over the past 50 years reveals only 9 welldocumented cases of Hodgkin's disease con ned to the craniospinal axis at presentation (Table 1 ). Tumors have been described as isolated cerebral or cerebellar masses or, less commonly, parenchymal disease with attachment to the dura or bone. In two cases, disease was con ned to the dura (Bender and Mayernik, 1986; Nagashima et al., 1980) . In one report, the primary CNS lesion was treated 3 months before lung involvement was ultimately discovered (Deckert-Schluter et al., 1998). Other case reports (Bertelsen, 1970; Burstein et al., 1963; Henry et al., 1974; Zimmerman, 1975) provide inadequate diagnostic information or have been reclassi ed as non-Hodgkin's lymphoma, an unsurprising nding given the evolving pathologic classi cation and staging methods over the period of this review.
Patients with immunode ciency are at increased risk of malignancy, including Hodgkin's disease (Gatti and Good, 1971; Rabkin et al., 1991 ). An increased risk of Hodgkin's disease has been con rmed in those infected with HIV (Hessol et al., 1992; Levine, 1998; Schoeppel et al., 1986; Serraino et al., 1997; Straus, 1997) . HIVinfected patients with Hodgkin's disease are more likely to present with B symptoms, mixed cellularity histology, extranodal involvement, and advanced stage of disease (Carbone et al., 1991; Tirelli et al., 1992) . Epstein-Barr virus infection is common in this population, particularly in those aged 50 years and older (Tirelli et al., 1995) . Primary CNS malignancies including high-grade non-Hodgkin's lymphoma and Kaposi's sarcoma have been associated with the low CD4 + count of HIV infection (Petruckevitch et al., 1999; Rubio, 1994) . A similar association has not been established for CNS Hodgkin's disease. However, as HIV-related Hodgkin's disease cases accumulate, a propensity for primary CNS involvement may emerge.
Interest in radiation-induced cancers has grown in recent years as the number of long-term survivors has increased. The results of epidemiologic reviews are of particular interest in this case because of the possible relationship between 131 I exposure and development of Hodgkin's disease. A number of population-based studies from the United States and Sweden have examined cancer incidence in patients undergoing diagnostic 131 I scans and therapeutic doses of I 131 for hyperthyroidism or thyroid cancer. These studies have reported an increased risk of some solid tumors (Goldman et al., 1988; Hoffman et al., 1982) and chronic myeloid leukemia (Shimon et al., 1995; Walgraeve et al., 1991) . An increase in the incidence of lymphoma or acute leukemia has not been observed (De Vathaire et al., 1997; Hall et al., 1992; Holm et al., 1991) . Large population-based reviews have not identi ed an increase in the relative risk of death from hematopoietic or lymphoreticular malignancy among patients treated with 131 I (Franklyn et al., 1998; Ron et al., 1998) . The weight of the evidence suggests that 131 I exposure is unlikely to be related to the pathogenesis of Hodgkin's disease in this case.
The optimum management of primary CNS Hodgkin's disease is not known. The role of chemotherapy is under active investigation in primary CNS lymphoma because of disappointing results with radiotherapy alone (Laperriere et al., 1997; Nelson et al., 1992; Neuwelt et al., 1991) . Chemotherapy is also playing a larger role in the management of localized extracranial Hodgkin's disease. In current risk-adapted treatment protocols, radiotherapy alone is limited to selected patients with favorable prognostic factors (Gospodarowicz et al., 1992; Specht et al., 1988) . Combined modality therapy has been recommended with increasing frequency for patients judged to be at risk of local or distant failure when treated with radiotherapy alone (Abrahamsen et al., 1996; Tubiana et al., 1985) .
The reported outcomes following treatment of primary CNS Hodgkin's disease (Table 1) suggest that the short-term prognosis for these patients is excellent. Seven of 8 evaluable patients remain alive and free of recurrence with follow-up ranging between 6 and 36 months.
Although 3 of the 9 reported cases were treated with chemotherapy, there is insuf cient data to recommend the routine use of adjunctive intrathecal or systemic chemotherapy without evidence of positive CSF cytology or extracranial extension. It is not clear if whole-brain irradiation is required to prevent intracranial relapse. Conclusions regarding treatment ef cacy are clearly limited by small numbers and lack of long term follow-up.
In summary, primary Hodgkin's disease limited to the CNS is exceedingly rare. The risk factors for this presentation remain unde ned. Although follow-up is short, radiotherapy alone appears to provide excellent disease-free survival. Chemotherapy may be reserved for patients with positive CSF, extracranial disease, or subsequent relapse.
